Is Edgewise Therapeutics, Inc. a good investment? Edgewise Therapeutics, Inc. (EWTX) is currently trading at 45.93 USD. Market analysts have a consensus price target of 55.42 USD. This suggests a potential upside from current levels.
In terms of valuation, the stock trades at a P/E ratio of 5.82. This relatively low multiple may signal that Edgewise Therapeutics, Inc. is undervalued compared to historical market norms.
Earnings Schedule: Edgewise Therapeutics, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -1.88.
No, it does not currently pay a dividend.
Edgewise Therapeutics, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of 8.38.
Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials; and EDG-15400, a novel small molecule for the treatment of heart failure with preserved ejection fraction. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. The company was incorporated in 2017 and is headquartered in Boulder, Colorado.
Community Discussion